ClinicalTrials.gg

Program

CDK2 Inhibitor ECI830

In Novartis’s pipeline, CDK2 inhibitor. Its studies are mostly in Small Cell Lung Carcinoma, led by Novartis.

Furthest: phase 2, since Dec 5, 20241 company-led study, 1 open or runningNext primary completion: Sep 25, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis11 open or runningphase 2since Dec 5, 2024Dec 5, 2024Sep 25, 2028phase 2 · NCT06726148
  • Named in Novartis’s own pipeline as ECI830, phase 1, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 5, 2024First study: phase 2 study in Small Cell Lung CarcinomaFirst studyNCT06726148 · 280 planned · United States, Australia, Canada and more

Ahead

  1. Sep 25, 2028Primary completion: phase 2 study in Small Cell Lung CarcinomaNCT06726148

TargetBeta

“CDK2 inhibitor”the company's pipeline, read by Claude · source
“An inhibitor of cyclin-dependent kinase 2 (CDK2), ”NCIt, by rule

Other programs on CDK2

ProgramCompanyFurthest phaseStudies
culmerciclibSino Biopharmaceuticalphase 311
CDK2 Inhibitor INCB123667ruleIncytephase 37
tegtociclibPfizerphase 24
vustanaciclibregor-pharmaceuticals-incphase 23
CDK2 Inhibitor AVZO-021ruleavenzo-therapeutics-incphase 22
CDK2 Degrader BG-75098ruleBeOne Medicinesphase 11
CG-7321rulechengdu-cynogen-bio-pharmaceutical-tech-co-ltdphase 11
nkt5097 cdk2rulenikang-therapeutics-incphase 11
ZE94-0605ruleeilean-therapeuticsphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06726148Small Cell Lung Carcinoma · United States, Australia, Canada and more2RecruitingSep 25, 2028280

How it is read

Names in the registry

  • “ECI830”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.